Patents by Inventor Christiane Jaeger
Christiane Jaeger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210253704Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: May 3, 2021Publication date: August 19, 2021Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane JAEGER, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
-
Publication number: 20200385470Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: August 18, 2020Publication date: December 10, 2020Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane JAEGER, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
-
Patent number: 10352943Abstract: This invention describes a new analytical method to determine the quantity and distribution of fucose per Fc within an antibody preparation.Type: GrantFiled: June 10, 2016Date of Patent: July 16, 2019Assignee: Roche Glycart AGInventors: Christiane Jaeger, Hans Koll, Peter Sondermann, Pablo Umana
-
Publication number: 20190177413Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: February 22, 2019Publication date: June 13, 2019Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane JAEGER, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
-
Publication number: 20190002565Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: September 18, 2018Publication date: January 3, 2019Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane JAEGER, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
-
Publication number: 20180312589Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: July 12, 2018Publication date: November 1, 2018Inventors: Marina BACAC, Thomas HOFER, Ralf HOSSE, Christiane JAEGER, Christian KLEIN, Ekkehard MOESSNER, Pablo UMANA, Tina WEINZIERL
-
Publication number: 20180265544Abstract: The present invention relates to a method for the separation of antibodies, specifically antibodies having different degrees of fucosylation. The method is based on binding affinity of antibodies to Fc receptors. The invention further relates to the use of Fc receptors for the separation of antibodies having different degrees of fucosylation.Type: ApplicationFiled: May 29, 2018Publication date: September 20, 2018Applicant: Roche Glycart AGInventors: Anne Freimoser-Grundschober, Christiane Jaeger, Peter Sondermann, Pablo Umana
-
Publication number: 20180222980Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: January 24, 2018Publication date: August 9, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane JAEGER, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
-
Publication number: 20180222981Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: January 24, 2018Publication date: August 9, 2018Inventors: Oliver AST, Marina BACAC, Sabine IMHOF-JUNG, Christiane JAEGER, Christian KLEIN, Stefan KLOSTERMANN, Michael MOLHOJ, Joerg Thomas REGULA, Wolfgang SCHAEFER, Pablo UMANA
-
Patent number: 9994610Abstract: The present invention relates to a method for the separation of antibodies, specifically antibodies having different degrees of fucosylation. The method is based on binding affinity of antibodies to Fc receptors. The invention further relates to the use of Fc receptors for the separation of antibodies having different degrees of fucosylation.Type: GrantFiled: October 16, 2012Date of Patent: June 12, 2018Assignee: ROCHE GLYCART AGInventors: Anne Freimoser-Grundschober, Christiane Jaeger, Peter Sondermann, Pablo Umana
-
Patent number: 9914776Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: GrantFiled: August 3, 2015Date of Patent: March 13, 2018Assignee: Hoffmann-La Roche Inc.Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Jaeger, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
Publication number: 20170327579Abstract: A bispecific antibody specifically binding to the extracellular domain of human BCMA and human CD3?, characterized in comprising a common antibody light chain is provided. Such bispecific antibody can be used as a medicament in the treatment of plasma cell disorders like Multiple Myeloma.Type: ApplicationFiled: November 18, 2015Publication date: November 16, 2017Inventors: MINH DIEM VU, KLAUS STREIN, OLIVER AST, MARINA BACAC, PETER BRUENKER, TANJA FAUTI, ANNE FREIMOSER-GRUNDSCHOBER, RAFT HOSSE, ADRIAN HUGENMATTER, CHRISTIANE JAEGER, CHRISTIAN KLEIN, EKKEHARD MOESSNER, Samuel MOSER, Pablo UMANA
-
Publication number: 20170108510Abstract: This invention describes a new analytical method to determine the quantity and distribution of fucose per Fc within an antibody preparation.Type: ApplicationFiled: June 10, 2016Publication date: April 20, 2017Applicant: Roche Glycart AGInventors: Christiane Jaeger, Hans Koll, Peter Sondermann, Pablo Umana
-
Publication number: 20160319036Abstract: The present invention relates to multispecific antibodies based on antibodies that share a common light chain. The multispecific antibodies include modified heavy chains comprising by domain exchange a common light chain variable domain VL; and two modified light chains comprising by domain exchange variable heavy chain domains of a first antibody (VH1) and a second antibody (VH2), wherein one light chain is of kappa isotype and one light chain is of lambda isotype. The present invention also relates to methods for the manufacture of said antibodies and their use.Type: ApplicationFiled: April 7, 2016Publication date: November 3, 2016Applicant: Hoffmann-La Roche Inc.Inventors: PETER BRUENKER, CHRISTIANE JAEGER, CHRISTIAN KLEIN, EKKEHARD MOESSNER, WOLFGANG SCHAEFER
-
Publication number: 20160145354Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: August 25, 2015Publication date: May 26, 2016Applicant: ROCHE GLYCART AGInventors: MARINA BACAC, PETER BRUENKER, CHRISTIANE JAEGER, CHRISTIAN KLEIN, EKKEHARD MOESSNER, PABLO UMANA, TINA WEINZIERL
-
Publication number: 20160130347Abstract: The present invention relates to bispecific antibodies comprising at least two Fab fragments, wherein the first Fab fragment comprises at least one antigen binding site specific for a first antigen; and the second Fab fragment comprises at least one antigen binding site specific for a second antigen, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged and the two Fab fragments are connected to each other by two peptide linkers; and wherein the bispecific antibody is devoid of a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: October 3, 2013Publication date: May 12, 2016Applicant: ROCHE GLYCART AGInventors: Peter Bruenker, Tanja Fauti, Christiane Jaeger, Christian Klein, Pablo UmaƱa
-
Publication number: 20160075785Abstract: The present invention generally relates to novel bispecific antigen binding molecules for T cell activation and re-direction to specific target cells. In addition, the present invention relates to polynucleotides encoding such bispecific antigen binding molecules, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the bispecific antigen binding molecules of the invention, and to methods of using these bispecific antigen binding molecules in the treatment of disease.Type: ApplicationFiled: August 3, 2015Publication date: March 17, 2016Applicant: HOFFMANN-LA ROCHE INC.Inventors: Oliver Ast, Marina Bacac, Sabine Imhof-Jung, Christiane Jaeger, Christian Klein, Stefan Klostermann, Michael Molhoj, Joerg Thomas Regula, Wolfgang Schaefer, Pablo Umana
-
BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE
Publication number: 20150274845Abstract: The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: May 5, 2014Publication date: October 1, 2015Applicant: Roche Glycart AGInventors: Peter Bruenker, Tanja Fauti, Christiane Jaeger, Christian Klein, Pablo Umana -
Publication number: 20140302544Abstract: This invention describes a new analytical method to determine the quantity and distribution of fucose per Fc within an antibody preparation.Type: ApplicationFiled: May 22, 2014Publication date: October 9, 2014Applicant: ROCHE GLYCART AGInventors: Christiane Jaeger, Hans Koll, Peter Sondermann, Pablo Umana
-
Publication number: 20140255399Abstract: The present invention relates to a method for the separation of antibodies, specifically antibodies having different degrees of fucosylation. The method is based on binding affinity of antibodies to Fc receptors. The invention further relates to the use of Fc receptors for the separation of antibodies having different degrees of fucosylation.Type: ApplicationFiled: October 16, 2012Publication date: September 11, 2014Applicant: ROCHE GLYCART AGInventors: Anne Freimoser-Grundschober, Christiane Jaeger, Peter Sondermann, Pablo Umana